LMNTD1

Summary

LMNTD1 (lamin tail domain containing 1, HGNC:26683) is a protein-coding gene on chromosome 12p12.1, encoding Lamin tail domain-containing protein 1 (Q8N9Z9).

Predicted to act upstream of or within cell population proliferation. Predicted to be located in intermediate filament and nucleus. Predicted to be active in cytoplasm and nuclear envelope.

Source: NCBI Gene 160492 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 64 total
• MANE Select transcript: NM_001145728

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26683
Approved symbol	LMNTD1
Name	lamin tail domain containing 1
Location	12p12.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ36004, Pas1c1
Ensembl gene	ENSG00000152936
Ensembl biotype	protein_coding
OMIM	617254
Entrez	160492

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000282881, ENST00000413632, ENST00000445693, ENST00000458174, ENST00000538178, ENST00000539523, ENST00000539744, ENST00000540106, ENST00000542224, ENST00000543629, ENST00000545543

RefSeq mRNA: 8 — MANE Select: NM_001145728 NM_001145727, NM_001145728, NM_001145729, NM_001256266, NM_001352232, NM_001352233, NM_001352234, NM_152590

CCDS: CCDS44847, CCDS44848, CCDS44849, CCDS58218, CCDS8704

Canonical transcript exons

ENST00000458174 — 10 exons

Exon	Start	End
ENSE00001007926	25519858	25520075
ENSE00001133292	25518795	25518967
ENSE00001189672	25526099	25526218
ENSE00001374826	25503738	25503800
ENSE00001779004	25552871	25552989
ENSE00002276634	25476082	25476460
ENSE00002307665	25553069	25553283
ENSE00003462265	25546374	25546554
ENSE00003500129	25549326	25549546
ENSE00003623895	25526769	25526955

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 85.50.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3738 / max 44.2381, expressed in 116 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130188	0.2485	81
130189	0.0552	17
130190	0.0499	13
130185	0.0098	3
130186	0.0083	4
130187	0.0020	1

Top tissues by expression

226 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	85.50	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.36	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.11	gold quality
left testis	UBERON:0004533	75.81	gold quality
right testis	UBERON:0004534	74.51	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	73.58	gold quality
testis	UBERON:0000473	73.45	gold quality
buccal mucosa cell	CL:0002336	67.80	silver quality
islet of Langerhans	UBERON:0000006	66.55	gold quality
bronchial epithelial cell	CL:0002328	64.43	gold quality
bronchus	UBERON:0002185	63.34	gold quality
fallopian tube	UBERON:0003889	62.25	gold quality
nasal cavity mucosa	UBERON:0001826	60.75	gold quality
mucosa of paranasal sinus	UBERON:0005030	59.47	gold quality
corpus callosum	UBERON:0002336	58.26	gold quality
sperm	CL:0000019	58.00	silver quality
smooth muscle tissue	UBERON:0001135	57.27	gold quality
left uterine tube	UBERON:0001303	55.46	gold quality
mucosa of transverse colon	UBERON:0004991	55.21	gold quality
hypothalamus	UBERON:0001898	53.68	gold quality
adenohypophysis	UBERON:0002196	53.09	gold quality
right lung	UBERON:0002167	52.52	gold quality
amygdala	UBERON:0001876	52.51	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	52.45	gold quality
pituitary gland	UBERON:0000007	52.41	gold quality
pancreas	UBERON:0001264	51.39	gold quality
spinal cord	UBERON:0002240	51.31	gold quality
caudate nucleus	UBERON:0001873	51.22	gold quality
rectum	UBERON:0001052	51.02	gold quality
adrenal tissue	UBERON:0018303	49.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.18

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

25 targeting LMNTD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-4690-5P	99.65	66.24	813
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-325	99.58	66.55	358
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-8070	99.07	69.30	1303
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-12135	98.99	70.26	1814
HSA-MIR-374A-3P	98.87	67.82	1531
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-4766-3P	98.48	67.94	1347
HSA-MIR-6865-3P	97.54	64.67	684
HSA-MIR-6503-3P	93.87	66.39	348

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lmntd1	ENSMUSG00000054966
rattus_norvegicus	Lmntd1	ENSRNOG00000015910
caenorhabditis_elegans		WBGENE00002067

Paralogs (68): KRT33A (ENSG00000006059), VIM (ENSG00000026025), KRT31 (ENSG00000094796), NEFM (ENSG00000104722), KRT23 (ENSG00000108244), KRT37 (ENSG00000108417), KRT32 (ENSG00000108759), KRT18 (ENSG00000111057), LMNB1 (ENSG00000113368), KRT36 (ENSG00000126337), KRT17 (ENSG00000128422), GFAP (ENSG00000131095), KRT34 (ENSG00000131737), KRT33B (ENSG00000131738), NES (ENSG00000132688), PRPH (ENSG00000135406), KRT85 (ENSG00000135443), KRT7 (ENSG00000135480), KRT71 (ENSG00000139648), INA (ENSG00000148798), LMNA (ENSG00000160789), KRT84 (ENSG00000161849), KRT82 (ENSG00000161850), KRT80 (ENSG00000167767), KRT1 (ENSG00000167768), KRT24 (ENSG00000167916), KRT8 (ENSG00000170421), KRT78 (ENSG00000170423), KRT86 (ENSG00000170442), KRT75 (ENSG00000170454), KRT6C (ENSG00000170465), KRT4 (ENSG00000170477), KRT74 (ENSG00000170484), KRT72 (ENSG00000170486), KRT83 (ENSG00000170523), BFSP2 (ENSG00000170819), KRT19 (ENSG00000171345), KRT15 (ENSG00000171346), KRT38 (ENSG00000171360), KRT13 (ENSG00000171401)

Protein

Protein identifiers

Lamin tail domain-containing protein 1 — Q8N9Z9 (reviewed: Q8N9Z9)

Alternative names: Intermediate filament tail domain-containing protein 1

All UniProt accessions (7): Q8N9Z9, F5H3Q3, F5H5I3, F5H719, F5H8G2, H0YFE3, H0YFH5

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the intermediate filament family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q8N9Z9-1	1	yes
Q8N9Z9-2	2
Q8N9Z9-3	3
Q8N9Z9-4	4
Q8N9Z9-5	5

RefSeq proteins (8): NP_001139199, NP_001139200, NP_001139201, NP_001243195, NP_001339161, NP_001339162, NP_001339163, NP_689803 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001322	Lamin_tail_dom	Domain
IPR036415	Lamin_tail_dom_sf	Homologous_superfamily
IPR042840	LMNTD1	Family

Pfam: PF00932

UniProt features (16 total): sequence variant 5, splice variant 5, sequence conflict 2, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N9Z9-F1	56.95	0.25

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 53 (showing top): TGACCTY_ERR1_Q2, GOCC_NUCLEAR_ENVELOPE, GOCC_INTERMEDIATE_FILAMENT_CYTOSKELETON, chr12p12, TCANNTGAY_SREBP1_01, ER_Q6_01, GOCC_ORGANELLE_ENVELOPE, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_D, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D, RAO_BOUND_BY_SALL4_ISOFORM_B, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_POLYMERIC_CYTOSKELETAL_FIBER, ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF, GOCC_SUPRAMOLECULAR_POLYMER, ZBTB18_TARGET_GENES

GO Biological Process (1): cell population proliferation (GO:0008283)

GO Molecular Function (0):

GO Cellular Component (4): nuclear envelope (GO:0005635), cytoplasm (GO:0005737), intermediate filament (GO:0005882), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	1
nucleus	1
endomembrane system	1
organelle envelope	1
intracellular anatomical structure	1
cellular anatomical structure	1
intermediate filament cytoskeleton	1
polymeric cytoskeletal fiber	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

686 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LMNTD1	IRAG2	Q12912	543
LMNTD1	LRRC74B	Q6ZQY2	528
LMNTD1	LRRC18	Q8N456	510
LMNTD1	DNAI7	Q6TDU7	477
LMNTD1	ETFRF1	Q6IPR1	474
LMNTD1	RASSF8	Q8NHQ8	471
LMNTD1	GPR87	Q9BY21	468
LMNTD1	ATP6AP1L	Q52LC2	461
LMNTD1	CSRNP3	Q8WYN3	453
LMNTD1	DTHD1	Q6ZMT9	439
LMNTD1	WDR48	Q8TAF3	435
LMNTD1	FAM114A2	Q9NRY5	411
LMNTD1	LRRC46	Q96FV0	410
LMNTD1	SHCBP1L	Q9BZQ2	410
LMNTD1	BCAT1	P54687	393

IntAct

2 interactions, top by confidence:

A	B	Type	Score
P		psi-mi:“MI:0914”(association)	0.350

BioGRID (3): BRCA1 (Two-hybrid), LMNTD1 (Proximity Label-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A2VE56, A6QPH9, I3LHS8, O08781, O14545, O54836, P0C6S7, Q14CM0, Q3SZY7, Q3U2E2, Q497H0, Q4R3D6, Q4R970, Q58D05, Q5F3F2, Q5FWF5, Q5R7S6, Q5RDJ2, Q5U2M7, Q5VT97, Q66J85, Q68FE8, Q69Z69, Q6DGF4, Q6FIF0, Q6N043, Q6P2K3, Q70EL2, Q7Z6G8, Q8BIZ1, Q8IWR0, Q8K214, Q8K387, Q8N7W2, Q8N9Z9, Q8NA31, Q8ND82, Q8QFX1, Q91YD3, Q96B23

Diamond homologs: A0A125S9M5, P11048, P14733, Q4R899, Q8N9Z9, Q9D4C1, A0A125S9M6, A6QQJ3, O76011, O77788, P02542, P02545, P04260, P04261, P04263, P05785, P07197, P08552, P08553, P08928, P09010, P10999, P12839, P13648, P14731, P14732, P15331, P16053, P16275, P20700, P21619, P21807, P21910, P23239, P23565, P35616, P41219, P46660, P48671, P48672

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	54
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1894 predictions. Top by Δscore:

Variant	Effect	Δscore
12:25503734:TTAC:T	donor_loss	1.0000
12:25503735:TACCT:T	donor_loss	1.0000
12:25503736:A:AC	donor_gain	1.0000
12:25503736:AC:A	donor_gain	1.0000
12:25503737:C:CT	donor_gain	1.0000
12:25503737:CC:C	donor_gain	1.0000
12:25503737:CCT:C	donor_gain	1.0000
12:25503799:CC:C	acceptor_gain	1.0000
12:25503800:CC:C	acceptor_gain	1.0000
12:25503801:C:CC	acceptor_gain	1.0000
12:25526097:A:AC	donor_gain	1.0000
12:25526098:C:CC	donor_gain	1.0000
12:25526760:TATAC:T	donor_loss	1.0000
12:25526761:ATAC:A	donor_loss	1.0000
12:25526762:TACT:T	donor_loss	1.0000
12:25526763:ACTC:A	donor_loss	1.0000
12:25526765:TCA:T	donor_loss	1.0000
12:25526767:A:AC	donor_gain	1.0000
12:25526767:A:T	donor_loss	1.0000
12:25526768:C:CA	donor_gain	1.0000
12:25526768:CT:C	donor_gain	1.0000
12:25526768:CTGTT:C	donor_gain	1.0000
12:25526785:G:A	donor_gain	1.0000
12:25526951:GAGAA:G	acceptor_gain	1.0000
12:25526952:AGAA:A	acceptor_gain	1.0000
12:25526953:GAA:G	acceptor_gain	1.0000
12:25526954:AA:A	acceptor_gain	1.0000
12:25526956:C:CC	acceptor_gain	1.0000
12:25526956:CTAGA:C	acceptor_loss	1.0000
12:25526957:T:G	acceptor_loss	1.0000

AlphaMissense

2677 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:25526809:A:G	F192S	0.994
12:25526851:A:G	L178P	0.993
12:25520069:C:G	A248P	0.991
12:25526851:A:T	L178H	0.991
12:25526217:A:T	V206E	0.988
12:25526808:G:C	F192L	0.988
12:25526808:G:T	F192L	0.988
12:25526810:A:G	F192L	0.988
12:25526118:A:G	L239P	0.987
12:25526167:A:G	W223R	0.987
12:25526167:A:T	W223R	0.987
12:25526215:A:G	W207R	0.987
12:25526215:A:T	W207R	0.987
12:25526848:T:G	Q179P	0.986
12:25526213:C:A	W207C	0.985
12:25526213:C:G	W207C	0.985
12:25526851:A:C	L178R	0.985
12:25520068:G:T	A248E	0.984
12:25526816:A:C	Y190D	0.984
12:25526845:T:G	Q180P	0.984
12:25526899:A:G	L162P	0.984
12:25526118:A:T	L239Q	0.983
12:25526809:A:C	F192C	0.983
12:25526148:A:G	F229S	0.980
12:25526892:G:C	N164K	0.980
12:25526892:G:T	N164K	0.980
12:25526212:C:G	A208P	0.978
12:25526118:A:C	L239R	0.976
12:25526935:A:T	I150K	0.976
12:25526172:A:G	F221S	0.974

dbSNP variants (sampled 300 via entrez): RS1000005853 (12:25555812 T>C), RS1000010909 (12:25601573 C>A), RS1000023981 (12:25523836 A>G,T), RS1000035930 (12:25570918 C>T), RS1000039449 (12:25561287 T>C), RS1000093333 (12:25520327 A>C), RS1000139663 (12:25523376 C>A,T), RS1000145834 (12:25565322 G>C), RS1000150402 (12:25562466 C>G,T), RS1000154865 (12:25476223 A>G), RS1000159327 (12:25578003 C>A,G), RS1000187137 (12:25496537 G>T), RS1000206582 (12:25564681 G>A), RS1000223845 (12:25642397 C>A,T), RS1000254321 (12:25545284 T>C)

Disease associations

OMIM: gene MIM:617254 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST003927_3	Dysmenorrheic pain	6.000000e-07
GCST007136_2	Resistant hypertension	2.000000e-07
GCST009144_15	Disease progression in age-related macular degeneration (adjusted for baseline)	3.000000e-06
GCST010120_2	Urinary volume	5.000000e-06
GCST010725_34	Malaria	6.000000e-06
GCST010725_77	Malaria	2.000000e-06
GCST90011898_14	Alanine aminotransferase levels	3.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007889	dysmenorrheic pain measurement
EFO:1002006	treatment-resistant hypertension
EFO:0008336	disease progression measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases methylation	1
testosterone undecanoate	affects cotreatment, increases expression	1
perfluorooctanoic acid	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	affects cotreatment, decreases expression	1
perfluorohexanesulfonic acid	affects cotreatment, decreases expression	1
abrine	increases expression	1
Arsenic	affects methylation	1
Calcitriol	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Levonorgestrel	affects cotreatment, increases expression	1
Asbestos, Crocidolite	affects methylation	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial